Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...

GSK reported core earnings of 59 cents per American ... Oncology sales rose 72%, driven by strong patient demand for Jemperli and Ojjaara Zejula sales fell 3% in the quarter.

GSK plc. GSK will report first-quarter 2024 results ... coupled with the recently launched blood cancer drug Ojjaara. Sales of these drugs are likely to offset the declining Blenrep sales, which ...

Omjjara (momelotinib) – which has been predicted by GSK to have blockbuster sales potential – was approved as Ojjaara by the US FDA in September after a three-month delay. It can be used in ...

Ojjaara (momelotinib) can cause side effects that range from mild to serious. More common side effects include fatigue and dizziness. If side effects from Ojjaara become difficult to tolerate ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...